ATE1

Across TCGA pan-cancer cohorts, ATE1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATE1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATE1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATE1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where ATE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.871	0.694	.001	47	view →
CCRCC	DFS	Tertile	III,IV	0.710	0.315	.011	23	view →
UCEC	OS	Tertile	III,IV	0.345	1.000	.010	12	view →
LUAD	DFS	Quartile	II,III,IV	0.778	0.981	.031	4	view →
HNSC	DFS	Quartile	IV	0.807	0.488	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATE1–PDAC (DFS)

Open the PDAC breakdown →